Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001
Feb 17, 2024 - Patience will be rewarded with these stocks.
0
These 3 Dividend Stocks Yield More Than 5% but Their Payout Ratios Are Over 100%. Are Dividend Cuts Coming?
https://www.fool.com/investing/2024/02/21/these-3-dividend-stocks-yield-more-than-5-but/?source=iedfolrf0000001
Feb 21, 2024 - Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is.
0
Pfizer (PFE) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2240265/pfizer-pfe-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2240265
Mar 13, 2024 - In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
0
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
https://www.zacks.com/stock/news/2245553/bayer-bayry-banks-on-pipeline-progress-amid-challenges?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245553
Mar 25, 2024 - Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
0
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
https://www.zacks.com/stock/news/2253861/will-novavax-s-nvax-strategic-reshaping-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253861
Apr 11, 2024 - To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
0
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
https://www.zacks.com/stock/news/2253860/will-pfizer-s-pfe-new-drugs-provide-a-boost-to-2024-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253860
Apr 11, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
Pfizer (PFE) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2259603/pfizer-pfe-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2259603
Apr 22, 2024 - Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
0
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
https://www.zacks.com/stock/news/2264363/here-s-how-to-play-pfizer-pfe-stock-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2264363
Apr 29, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0
Page 1>